PROGRESS toward the development of new therapies for osteoporosis was reported at the Second International Conference on Research Advances in Osteoporosis, in Arlington, Va, sponsored by the National Osteoporosis Foundation, the American Society for Bone and Mineral Research, and the National Institutes of Health.
Among the treatments showing promise in clinical trials are diphosphonates and a nasal-spray form of calcitonin. Preliminary findings from a yet unpublished study, suggesting that a new, combined hormone therapy may actually increase spinal bone density in osteoporotic women, also were reported.
While calcitonin-salmon (Calcimar, manufactured by Rorer Pharmaceuticals, Fort Washington, Pa) is currently approved for the treatment of established osteoporosis where estrogen is contraindicated, it is not used for prevention because it requires regular injections. In a controlled study conducted by Claus Christiansen, MD, Glostrup (Denmark) Hospital, involving 37 women with established postmenopausal osteoporosis, a new, nasal-spray form of the drug has been shown to